Luffa cylindrica suppresses development of Dermatophagoides farinae-induced atopic dermatitis-like skin lesions in Nc/Nga mice

Abstract Context: The fruit pulp of Luffa cylindrica Roemer (Cucurbitaceae) (LC) has been used to induce hemostasis, resolve phlegm and clear fever in traditional Korean medicine. However, the efficacy of LC has not been examined in atopic dermatitis (AD). Objective: A 70% ethanol extract of LC was evaluated to determine anti-inflammation and anti-AD effects in vitro and in vivo. Materials and methods: The inhibitory effects of LC on the production of PGE2 and histamine were respectively measured in lipopolysaccharide-treated (1 μg/mL) RAW264.7 macrophages and phorbol-12 myristate 13-acetate (50 nM) and A23187 (1 µM)-stimulated HMC-1 mast cells. The production of AD-related chemokines (RANTES, TARC, and MDC) were evaluated in IFN-γ and TNF-α-stimulated (10 ng/mL, each) HaCaT keratinocytes. LC (10 mg/mouse/d) was topically applied to the dorsal skin and ears of Dermatophagoides farina (Pyroglyphidae)-sensitized Nc/Nga mice for 4 weeks. Results: The IC50 values of LC on PGE2 and histamine production were 16.89 and 139.9 μg/mL, individually. The production of TARC and RANTES were inhibited 20% and 12% by LC (50 μg/mL) in HaCaT cells, respectively (p < 0.05). In sensitized-NC/Nga mice, the plasma levels of IgE and histamine were suppressed 36% and 41% by LC, respectively (p < 0.05). LC also reduced hemorrhage, hypertrophy, and hyperkeratosis of the epidermis and infiltration of mast cells in the dorsal skin and ear. Discussion and conclusion: LC can inhibit AD-like skin lesions and reduce the generation of IgE via inhibition of the inflammatory responses. LC has potential as a therapeutic agent to treat allergic diseases, including AD.

[1]  W. Carr Topical Calcineurin Inhibitors for Atopic Dermatitis: Review and Treatment Recommendations , 2013, Pediatric Drugs.

[2]  T. Kao,et al.  Functional components in Luffa cylindrica and their effects on anti-inflammation of macrophage cells. , 2012, Food chemistry.

[3]  J. Ring,et al.  Guidelines for treatment of atopic eczema (atopic dermatitis) Part II , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  J. Ring,et al.  Guidelines for treatment of atopic eczema (atopic dermatitis) Part I , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  H. Ha,et al.  Angelicae Dahuricae Radix Inhibits Dust Mite Extract-Induced Atopic Dermatitis-Like Skin Lesions in NC/Nga Mice , 2012, Evidence-based complementary and alternative medicine : eCAM.

[6]  T. Kosaka,et al.  Prior or coinstantaneous oral exposure to environmental immunosuppressive agents aggravates mite allergen-induced atopic dermatitis-like immunoreaction in NC/Nga mice. , 2011, Toxicology.

[7]  P. Shaw,et al.  Structural characterization and anti-HIV-1 activities of arginine/glutamate-rich polypeptide Luffin P1 from the seeds of sponge gourd (Luffa cylindrica). , 2011, Journal of structural biology.

[8]  Fu-Tong Liu,et al.  IgE, Mast Cells, and Eosinophils in Atopic Dermatitis , 2011, Clinical reviews in allergy & immunology.

[9]  F. He,et al.  Cloning and soluble expression of mature alpha-luffin from Luffa cylindrica and its antitumor activities in vitro. , 2010, Acta biochimica et biophysica Sinica.

[10]  T. Terui Analysis of the mechanism for the development of allergic skin inflammation and the application for its treatment: overview of the pathophysiology of atopic dermatitis. , 2009, Journal of pharmacological sciences.

[11]  A. Gupta,et al.  Immunomodulatory effects of two sapogenins 1 and 2 isolated from Luffa cylindrica in Balb/C mice. , 2007, Bioorganic & medicinal chemistry letters.

[12]  Giampiero Girolomoni,et al.  The contribution of keratinocytes to the pathogenesis of atopic dermatitis. , 2006, European journal of dermatology : EJD.

[13]  C. Duez,et al.  Dendritic cells and toll-like receptors in allergy and asthma. , 2006, European journal of dermatology : EJD.

[14]  H. Williams,et al.  Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials , 2005, BMJ : British Medical Journal.

[15]  D. Margolis,et al.  Guidelines of care for atopic dermatitis , 2004 .

[16]  T. Luger,et al.  The treatment of atopic dermatitis with topical immunomodulators. , 2003, Clinics in dermatology.

[17]  M. Boguniewicz,et al.  A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. Pediatric Tacrolimus Study Group. , 1998, The Journal of allergy and clinical immunology.

[18]  N. Ishii,et al.  Predominance of type 2 cytokine-producing CD4+ and CD8+ cells in patients with atopic dermatitis. , 1997, The Journal of allergy and clinical immunology.

[19]  H. Tagami,et al.  Successful treatment of resistant facial lesions of atopic dermatitis with 0.1% FK506 ointment , 1995, The British journal of dermatology.

[20]  D. Leung,et al.  Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. , 1995, The Journal of allergy and clinical immunology.

[21]  M. Tabata,et al.  Anti-Allergic Effect of Bryonolic Acid from Luffa cylindrica Cell Suspension Cultures , 1991, Planta medica.

[22]  J. Hornung,et al.  Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line , 1988, The Journal of cell biology.